MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (Nasdaq: GTXI), announced today that it has initiated the Phase IIb clinical trial evaluating Ostarine™, a selective androgen receptor modulator, or SARM, for the treatment of cancer cachexia.
MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (Nasdaq: GTXI), announced today that it has initiated the Phase IIb clinical trial evaluating Ostarine™, a selective androgen receptor modulator, or SARM, for the treatment of cancer cachexia.
